Clinical trials: Pulmonary Tuberculosis
Tuberculosis, Tuberculosis, Pulmonary
Point-of-care Triage Test for Active Tuberculosis
Background: Tuberculosis (TB) is a bacterial lung infection leaving 3.6 million people undiagnosed each year. Thirty percent of infected people do not receive treatment due to failure to receive diagnostic testing or being lost…
- Trial name
- TriageTB (NCT04232618)
- Testing
- Multi-biomarker point-of-care test
- Where
- South Africa
- Volunteers
- 900 people
- Sponsor
- University of Stellenbosch
Lung Diseases, Tuberculosis
Effectiveness of Public Health Model of Latent Tuberculosis Infection Control for High-Risk Adolescents
This study will determine the differential cumulative mean number of isoniazid (INH) pills completed over 9 to 12 months for adolescents assigned to one of the following two groups: 1) peer adherence coaching, parent training…
- Trial name
- NCT00233168
- Testing
- Adherence Program, Life Skills and Self-Esteem Training Program (Attention Control Arm)
- Where
- United States
- Volunteers
- 263 people
- Sponsor
- San Diego State University
HIV Infections, Tuberculosis
The Treatment of Tuberculosis in HIV-Infected Patients
PER 5/30/95 AMENDMENT: To compare the combined rate of failure during therapy and relapse after therapy between two durations of intermittent therapy (6 versus 9 months) for the treatment of pulmonary tuberculosis (TB) in…
- Trial name
- NCT00001033
- Testing
- Ethambutol hydrochloride, Isoniazid, Pyrazinamide
- Where
- 12 sites in United States
- Volunteers
- 650 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pulmonary Tuberculosis
Pharmacokinetic Study of Patients Who Undergo Cycloserine, a 2nd-line Antituberculosis Medicament
In all treatments of tuberculosis, the second-line drugs are usually less effective but have more drug toxicity than the first-line ones.
- Trial name
- CSPK (NCT01002170)
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- Taipei Medical University WanFang Hospital
Tuberculosis, Multidrug-Resistant, Extensively Drug-Resistant Tuberculosis
Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)
TB PRACTECAL is a multi-centre, open label, multi-arm, randomised, controlled, phase II-III trial; evaluating short treatment regimens containing bedaquiline and pretomanid in combination with existing and re-purposed anti-TB…
- Conditions
- Tuberculosis, Multidrug-Resistant, Extensively Drug-Resistant Tuberculosis, Tuberculosis, Pulmonary
- Trial name
- TB-PRACTECAL (NCT02589782)
- Testing
- Bedaquiline, Pretomanid, Moxifloxacin
- Where
- 7 sites in Belarus, South Africa and 1 more
- Volunteers
- 552 people
- Sponsor
- Medecins Sans Frontieres, Netherlands
Lung Diseases, Tuberculosis
Promoting Adherence to TB Regimens in Latino Adolescents
To test a public health model of screening, preventive isoniazid treatment, and adherence counseling plus medical education of primary care clinicians to enhance their skills and attention to TB control.
- Trial name
- NCT00005738
- Sponsor
- San Diego State University
Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant
Various Doses and Durations of Linezolid Plus Bedaquiline & Pretomanid in Participants With Drug Resistant Tuberculosis
To evaluate the efficacy, safety and tolerability of various doses and durations of linezolid plus bedaquiline and pretomanid after 26 weeks of treatment in participants with either pulmonary XDR-TB, pre-XDR-TB, or treatment…
- Conditions
- Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant, Tuberculosis, MDR, Tuberculosis
- Trial name
- ZeNix (NCT03086486)
- Testing
- Pretomanid, Linezolid, Bedaquiline
- Where
- 11 sites in Georgia, Moldova and 2 more
- Volunteers
- 181 people
- Sponsor
- Global Alliance for TB Drug Development
Cystic Fibrosis, Nontuberculous Mycobacterial Lung Disease
Mycobacteriophage Treatment of Non-tuberculosis Mycobacteria
About 10 people with cystic fibrosis (CF) and persistent Nontuberculosis mycobacteria (NTM) infection despite treatment will be screened to find out if their NTM infection has at least one mycobacteriophage that is effective in…
- Conditions
- Cystic Fibrosis, Nontuberculous Mycobacterial Lung Disease, Nontuberculous Mycobacterium Infection, Mycobacterium Infections
- Trial name
- POSTSTAMP (NCT06262282)
- Testing
- mycobacteriophage
- Where
- 18 sites in United States
- Volunteers
- 10 people
- Sponsor
- National Jewish Health
Pulmonary Tuberculosis
Prospective Study of N-acetyltransferase2 (NAT2) and Cytochrome P4502E1 (CYP2E1) Gene as Susceptible Risk Factors for Antituberculosis (ATT) Induced Hepatitis
N-acetyltransferase2 (NAT2) and Cytochrome P4502E1 (CYP2E1) are two drug metabolizing enzymes. Antituberculosis drug isoniazid is acetylated by NAT2 and forms ultimately a nontoxic compound which is metabolized by CYP2E1 to a…
- Trial name
- NCT00834353
- Testing
- ATT
- Where
- India
- Volunteers
- healthy volunteers welcome
- Sponsor
- Maulana Azad Medical College
Tuberculosis, Pulmonary
Integrated Discovery and Development of Innovative TB Diagnostics
The long term goal of this project is to provide information critical to the development and use of a low-cost, point-of-care, rapid, simple, and highly accurate diagnostic tool that can help clinicians make a microbiological…
- Trial name
- (CETR) (NCT06624501)
- Testing
- Observational cohort study
- Volunteers
- 1,450 people, healthy volunteers welcome
- Sponsor
- Harvard University Faculty of Medicine
Tuberculosis, Multidrug-Resistant
Pharmacokinetic Study to Evaluate Anti-mycobacterial Activity of TMC207 in Combination With Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for Treatment of Children/Adolescents With Pulmonary MDR-TB
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (explores what the body does to the drug), and anti-mycobacterial activity of bedaquiline (TMC207) in children and adolescents (0 months to less…
- Trial name
- NCT02354014
- Testing
- Bedaquiline (TMC207), Background Regimen (BR)
- Where
- 11 sites in Mozambique, Philippines and 4 more
- Volunteers
- 60 people
- Sponsor
- Janssen Research & Development, LLC
HIV Infections, Tuberculosis Infection
European Pregnancy and Paediatric Infections Cohort Collaboration: Paediatric Protocol
Across Europe and worldwide, there are many studies following groups (cohorts) of children living with human immunodeficiency virus (HIV) and other infections over time, to monitor their long-term health.
- Conditions
- HIV Infections, Tuberculosis Infection, Hepatitis C, Covid19
- Trial name
- EPPICC (NCT04677842)
- Testing
- ART Therapy
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- PENTA Foundation
Rifampicin-Resistant Pulmonary Tuberculosis, Multidrug-Resistant Pulmonary Tuberculosis
A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis
This is a Phase 3, randomized, open-label, active-controlled, multicenter trial evaluating the efficacy, safety, and tolerability of quabodepistat-containing regimens for the treatment of rifampicin-resistant or…
- Trial name
- QUANTUM-TB (NCT07209761)
- Testing
- Bedaquiline, Quabodepistat, Pretomanid
- Where
- 42 sites in China, Georgia and 8 more
- Volunteers
- 532 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Cystic Fibrosis, Pediatrics
A Prospective, Multicenter, Collaborative Study to Determine the Prevalence of Nontuberculous Mycobacteria (NTM) in Pediatric Patients With Cystic Fibrosis in Florida
To determine the prevalence of nontuberculous mycobacterial infection (NTM) in pediatric patients with cystic fibrosis in the State fo Florida.
- Trial name
- NCT02198079
- Testing
- Sputum
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- University of Miami
Active Tuberculosis, Latent Tuberculosis Infection
Performance Evaluation of the VIDAS TB-IGRA Assay.
This study will evaluate the performance of the VIDAS® Interferon Gamma (IFN-γ) Release Assay (TB-IGRA) assay, which is intended for use as an aid in the diagnosis of tuberculosis infection.
- Conditions
- Active Tuberculosis, Latent Tuberculosis Infection, Non-Tuberculous Mycobacterial (NTM) Pneumonia
- Trial name
- NCT04048018
- Testing
- Blood draw and IGRA test
- Where
- 24 sites in United States, Brazil and 7 more
- Volunteers
- 2,401 people, healthy volunteers welcome
- Sponsor
- BioMérieux
COVID-19, HIV Seropositivity
Collision of Three Global Pandemics: the Effect of Tuberculosis and HIV on the Epidemiological, Clinical, Virological and Immunological Trajectory of COVID-19 in Botswana and Namibia
COVID-19 has emerged as global pandemic during the past few months, with an unprecedented impact on public health, and society more generally.
- Conditions
- COVID-19, HIV Seropositivity, Tuberculosis, Pulmonary, Tuberculosis Infection
- Trial name
- Core-NB (NCT05268380)
- Testing
- Covid-19, TB and HIV diagnosis
- Where
- Namibia
- Volunteers
- 1,750 people
- Sponsor
- University of Namibia
Tuberculosis, Pulmonary, Mycobacterium Tuberculous
Utility of MODS for Diagnosis of MDR-TB and Second-Line Antituberculous Drug Susceptibility Testing in Mali
Background: -Tuberculosis (TB) is an infection of the lungs caused by bacteria. In Mali, TB is diagnosed with a test that is fast and inexpensive but not always accurate.
- Conditions
- Tuberculosis, Pulmonary, Mycobacterium Tuberculous, Antitubercular Agents, Tuberculosis, Mulutidrug-Resistant
- Trial name
- NCT01381757
- Where
- 2 sites in United States, Mali
- Volunteers
- 34 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Lung Diseases, Tuberculosis
TB Contact Investigation: Behavioral Intervention
To develop a behavioral intervention aimed at public health workers who perform tuberculosis contact investigation and designed to enhance the contact investigation process.
- Trial name
- NCT00005740
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Pulmonary Tuberculosis (TB)
ATORvastatin in Pulmonary TUBerculosis: a POPulation PharmacoKinetics -PharmacoDynamics Sub-study (ATORTUB popPK-PD)
The purpose of this study is to assess pharmacokinetic parameters of atorvastatin at different doses when combined with the standard first line tuberculosis (TB) treatment regimen in adults with drug sensitive pulmonary TB.
- Trial name
- NCT07303699
- Testing
- Atorvastatin 20 mg, Atorvastatin 40 mg, Atorvastatin 60 mg
- Where
- 3 sites in Nigeria
- Volunteers
- 80 people
- Sponsor
- Obafemi Awolowo University Teaching Hospital
Pulmonary Tuberculosis
A Phase 3 Trial Assessing Safety and Efficacy of B-Pa-L in Participants With DR-TB
The purpose of this study is to evaluate the efficacy, safety, tolerability and pharmacokinetics of bedaquiline plus PA-824 plus linezolid after 6 months of treatment (option for 9 months for participants who remain culture…
- Trial name
- NCT02333799
- Testing
- Bedaquiline, PA-824, Linezolid
- Where
- 3 sites in South Africa
- Volunteers
- 109 people
- Sponsor
- Global Alliance for TB Drug Development